Dear reader of ADxS.org, please excuse the disruption.

ADxS.org needs around €58,500 in 2024. Unfortunately 99,8 % of our readers do not donate. If everyone reading this appeal made a small contribution, our fundraising campaign for 2024 would be over after a few days. This appeal is displayed 23,000 times a week, but only 75 people donate. If you find ADxS.org useful, please take a minute to support ADxS.org with your donation. Thank you very much!

Since 01.06.2021 ADxS.org is supported by the non-profit ADxS e.V. Donations to ADxS e.V. are tax-deductible in Germany (up to €300, the remittance slip is sufficient as a donation receipt).

If you would prefer to make an active contribution, you can find ideas for Participation or active support here.

$39778 of $63500 - as of 2024-09-30
62%
Header Image
Reboxetine for ADHD

Sitemap

Reboxetine for ADHD

Reboxetine is a noradrenaline reuptake inhibitor, as well as a weak serotonin reuptake inhibitor.

Trade names: Edronax (D, CH, A), Solcenx (D)

The active ingredient reboxetine is a noradrenergic drug which, according to individual reports, can be effective for ADHD. As an antidepressant, as it was actually intended to be, it was probably quite unsuccessful.

The updated European consensus on the diagnosis and treatment of ADHD (2018) names reboxetine as a possible alternative to atomoxetine for ADHD.1

There is evidence that reboxetine is effective for ADHD. However, there are only a few controlled studies. Reboxetine could be used primarily in adults without comorbidities.23

Reboxetine is not reimbursed by health insurance companies in Germany.